The EIF5A2 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited heterogeneous knockout population derived from the HeLa cell line, engineered for targeted disruption of the EIF5A2 gene. This polyclonal product comprises a pool of cells with diverse editing outcomes, offering a robust loss-of-function model to interrogate the biological roles of eukaryotic translation initiation factor 5A2. The use of CRISPR/Cas9 technology enables efficient ablation of gene function without prior knowledge of specific mutation types, making these cells a versatile tool for functional studies in cancer research.
HeLa is an immortalized epithelial cell line originally isolated from a cervical adenocarcinoma, and it remains one of the most extensively used models in cancer biology. These cells display aggressive growth characteristics, including rapid proliferation, anchorage-independent growth, and high transfection efficiency, which facilitate genetic manipulation and downstream phenotypic analyses. The HeLa background provides a well-characterized platform for studying genes implicated in cervical cancer progression, metastasis, and therapeutic response.
EIF5A2 encodes a translation elongation factor that specifically promotes the synthesis of proteins containing polyproline stretches, a function dependent on its unique hypusine modification catalyzed by deoxyhypusine synthase (DHPS) and deoxyhypusine hydroxylase (DOHH). This factor is transcriptionally regulated by MYC and STAT3, and its activity is integrated within mTORC1 and TGF-?? signaling cascades. Key downstream targets of EIF5A2-mediated translation include the cell cycle regulator cyclin D1, matrix metalloproteinases MMP-2 and MMP-9, and anti-apoptotic factors BCL2 and survivin (BIRC5). Consequently, EIF5A2 operates at the nexus of proliferative and invasive signaling networks, and it interacts with ribosomal proteins and the nuclear export factor CRM1 (XPO1) to execute its functions.
In the HeLa cervical adenocarcinoma context, EIF5A2 ablation attenuates the synthesis of these proline-rich oncogenic proteins, leading to impaired cell cycle progression, reduced survival signaling, and diminished invasive capacity. This knockout model thus recapitulates critical aspects of EIF5A2-dependent malignancy, allowing dissection of how translation control mechanisms contribute to tumorigenesis. The polyclonal nature of the knockout population enables analysis of the overall impact of gene disruption on cellular phenotypes without clonal artifacts, enhancing reproducibility in functional assays.
Widely applicable to cancer biology and translational research, these cells support a variety of experimental approaches, including Western blotting and RT-qPCR monitoring of target and downstream effectors, MTT assays for viability, wound healing and transwell invasion assays for migratory properties, and flow cytometry for cell cycle profiling. The product is also suited for RNA-sequencing studies to characterize global transcriptomic changes following EIF5A2 loss. Researchers investigating mTORC1/MYC-driven translation, metastasis mechanisms, or drug target validation will find this model valuable. For further details, please contact Ascent Research.
